Evaluating the Efficacy of Topical PF-07038124 in Managing Atopic Dermatitis and Plaque Psoriasis
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on February 9th, 2024
|
Currently, corticosteroid ointments are the topical treatment of choice for atopic dermatitis and plaque psoriasis. However, this approach is linked to significant systemic adverse events. The underlying immune response in these conditions is driven by cytokines from type 2 Helper T-cells, including IL-4, IL-13, TNF-alpha, and others. Consequently, a study was undertaken to explore the potential of PF-07038124, a phosphodiesterase-4 inhibitor capable of disrupting intracellular signal amplification, in the treatment of atopic dermatitis and plaque psoriasis.
The phase 2 clinical study involved 104 patients diagnosed with atopic dermatitis, affecting 5% to 20% of their body surface area. Disease severity was assessed at baseline using the Eczema Area and Severity Index (EASI) or the Psoriasis Area and Severity Index (PASI). Randomly assigned to receive either 0.01% PF-07038124 or a placebo topically. After 6 weeks of treatment, those who received an ointment containing 0.01% PF-07038124, experienced a significant reduction in atopic dermatitis and plaque psoriasis. To be specific, there was a 74.9% reduction in EASI score and a 4.8 reduction in PASI score. In contrast, the placebo group showed a 35.5% reduction in EASI score and a 0.1 increase in PASI score. Safety analysis indicated no significant difference in the rate of adverse events between the two groups.
The phase 2 clinical study involved 104 patients diagnosed with atopic dermatitis, affecting 5% to 20% of their body surface area. Disease severity was assessed at baseline using the Eczema Area and Severity Index (EASI) or the Psoriasis Area and Severity Index (PASI). Randomly assigned to receive either 0.01% PF-07038124 or a placebo topically. After 6 weeks of treatment, those who received an ointment containing 0.01% PF-07038124, experienced a significant reduction in atopic dermatitis and plaque psoriasis. To be specific, there was a 74.9% reduction in EASI score and a 4.8 reduction in PASI score. In contrast, the placebo group showed a 35.5% reduction in EASI score and a 0.1 increase in PASI score. Safety analysis indicated no significant difference in the rate of adverse events between the two groups.